| NCT04195555 |
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT04195555 |
Recruiting |
National Cancer Institute (NCI) |
2025-12-31 |
| NCT04106219 |
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT04106219 |
Recruiting |
Eli Lilly and Company |
2024-04-17 |
| NCT03698994 |
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03698994 |
Recruiting |
National Cancer Institute (NCI) |
2025-12-31 |
| NCT03526250 |
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03526250 |
Recruiting |
National Cancer Institute (NCI) |
2025-06-30 |
| NCT03373097 |
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03373097 |
Recruiting |
Bambino Gesù Hospital and Research Institute |
2024-12-31 |
| NCT03363373 |
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow |
https://ClinicalTrials.gov/show/NCT03363373 |
Recruiting |
Y-mAbs Therapeutics |
2024-11-30 |
| NCT03294954 |
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03294954 |
Recruiting |
Baylor College of Medicine |
2021-09-01 |
| NCT03291080 |
Oral Liquid 13-cis-retinoic Acid (13-CRA) |
https://ClinicalTrials.gov/show/NCT03291080 |
Completed |
Nova Laboratories Limited |
2019-09-12 |
| NCT03275402 |
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases |
https://ClinicalTrials.gov/show/NCT03275402 |
Recruiting |
Y-mAbs Therapeutics |
2020-12-31 |
| NCT03273712 |
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) |
https://ClinicalTrials.gov/show/NCT03273712 |
Recruiting |
University of Iowa |
2020-01-31 |
| NCT03242603 |
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells |
https://ClinicalTrials.gov/show/NCT03242603 |
Recruiting |
National University Hospital, Singapore |
2019-08-15 |
| NCT03236857 |
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies |
https://ClinicalTrials.gov/show/NCT03236857 |
Recruiting |
AbbVie |
2022-04-07 |
| NCT03189706 |
Study of Chemoimmunotherapy for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03189706 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-06-30 |
| NCT03165292 |
Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy |
https://ClinicalTrials.gov/show/NCT03165292 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2023-06-30 |
| NCT03126916 |
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma |
https://ClinicalTrials.gov/show/NCT03126916 |
Recruiting |
Children’s Oncology Group |
2026-09-30 |
| NCT03107988 |
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) |
https://ClinicalTrials.gov/show/NCT03107988 |
Recruiting |
New Approaches to Neuroblastoma Therapy Consortium |
2020-05-31 |
| NCT03061656 |
Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03061656 |
Active, not recruiting |
Samsung Medical Center |
2013-12-31 |
| NCT03042429 |
Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients |
https://ClinicalTrials.gov/show/NCT03042429 |
Completed |
University of Cologne |
2016-12-31 |
| NCT03042416 |
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety |
https://ClinicalTrials.gov/show/NCT03042416 |
Recruiting |
University of Alberta |
2021-12-31 |
| NCT03033303 |
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03033303 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2022-06-30 |
| NCT03233204 |
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03233204 |
Recruiting |
National Cancer Institute (NCI) |
2024-09-30 |
| NCT02998983 |
Racotumomab in Patients With High-risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02998983 |
Recruiting |
Laboratorio Elea Phoenix S.A. |
2020-12-31 |
| NCT02982941 |
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors |
https://ClinicalTrials.gov/show/NCT02982941 |
Completed |
MacroGenics |
2019-05-22 |
| NCT02933333 |
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor |
https://ClinicalTrials.gov/show/NCT02933333 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-08-30 |
| NCT02924324 |
Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients |
https://ClinicalTrials.gov/show/NCT02924324 |
Completed |
Memorial Sloan Kettering Cancer Center |
2019-11-30 |
| NCT02919046 |
Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children |
https://ClinicalTrials.gov/show/NCT02919046 |
Recruiting |
Sinobioway Cell Therapy Co., Ltd. |
2020-09-30 |
| NCT02914405 |
Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02914405 |
Recruiting |
University Hospital Southampton NHS Foundation Trust |
2020-05-31 |
| NCT02909777 |
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma |
https://ClinicalTrials.gov/show/NCT02909777 |
Recruiting |
Dana-Farber Cancer Institute |
2020-10-31 |
| NCT02864563 |
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification |
https://ClinicalTrials.gov/show/NCT02864563 |
Recruiting |
Institut Curie |
2021-12-31 |
| NCT03220035 |
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03220035 |
Recruiting |
National Cancer Institute (NCI) |
2023-12-31 |
| NCT03213704 |
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03213704 |
Recruiting |
National Cancer Institute (NCI) |
2024-09-30 |
| NCT02786719 |
High-Risk Neuroblastoma Chemotherapy Without G-CSF |
https://ClinicalTrials.gov/show/NCT02786719 |
Completed |
Baylor College of Medicine |
2019-02-05 |
| NCT02780128 |
Next Generation Personalized Neuroblastoma Therapy |
https://ClinicalTrials.gov/show/NCT02780128 |
Recruiting |
Children’s Hospital of Philadelphia |
2021-07-31 |
| NCT02771743 |
Response-based Treatment of High-risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02771743 |
Recruiting |
Samsung Medical Center |
2020-03-31 |
| NCT02765243 |
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02765243 |
Recruiting |
Zhujiang Hospital |
2019-05-12 |
| NCT02761915 |
A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART) |
https://ClinicalTrials.gov/show/NCT02761915 |
Recruiting |
Cancer Research UK |
2023-02-28 |
| NCT02748135 |
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma |
https://ClinicalTrials.gov/show/NCT02748135 |
Recruiting |
Oncurious NV |
2022-06-30 |
| NCT02743429 |
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02743429 |
Active, not recruiting |
University Medicine Greifswald |
2023-12-31 |
| NCT03213678 |
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03213678 |
Recruiting |
National Cancer Institute (NCI) |
2024-09-30 |
| NCT02679144 |
Neuroblastoma Maintenance Therapy Trial |
https://ClinicalTrials.gov/show/NCT02679144 |
Recruiting |
Spectrum Health Hospitals |
2021-02-28 |
| NCT03213665 |
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03213665 |
Recruiting |
National Cancer Institute (NCI) |
2024-09-30 |
| NCT02650648 |
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02650648 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT02644460 |
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02644460 |
Recruiting |
Emory University |
2020-12-31 |
| NCT02641314 |
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02641314 |
Recruiting |
University of Cologne |
2020-10-31 |
| NCT02605421 |
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02605421 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2020-07-31 |
| NCT03213652 |
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03213652 |
Recruiting |
National Cancer Institute (NCI) |
2024-09-30 |
| NCT02573896 |
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells |
https://ClinicalTrials.gov/show/NCT02573896 |
Recruiting |
New Approaches to Neuroblastoma Therapy Consortium |
2021-01-31 |
| NCT03210714 |
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03210714 |
Recruiting |
National Cancer Institute (NCI) |
2024-12-31 |
| NCT03155620 |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
https://ClinicalTrials.gov/show/NCT03155620 |
Recruiting |
National Cancer Institute (NCI) |
2027-09-30 |
| NCT03721068 |
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03721068 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2024-06-19 |
| NCT00107289 |
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma |
https://ClinicalTrials.gov/show/NCT00107289 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT02559778 |
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy |
https://ClinicalTrials.gov/show/NCT02559778 |
Recruiting |
Spectrum Health Hospitals |
2025-09-30 |
| NCT03541720 |
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma |
https://ClinicalTrials.gov/show/NCT03541720 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2021-01-01 |
| NCT02035137 |
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat |
https://ClinicalTrials.gov/show/NCT02035137 |
Active, not recruiting |
New Approaches to Neuroblastoma Therapy Consortium |
2020-01-31 |
| NCT00840047 |
Methionine PET/CT Studies In Patients With Cancer |
https://ClinicalTrials.gov/show/NCT00840047 |
Recruiting |
St. Jude Children’s Research Hospital |
2027-07-27 |
| NCT02536183 |
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02536183 |
Recruiting |
Children’s National Research Institute |
2020-10-31 |
| NCT02508038 |
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors |
https://ClinicalTrials.gov/show/NCT02508038 |
Recruiting |
University of Wisconsin, Madison |
2021-05-31 |
| NCT02452554 |
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma |
https://ClinicalTrials.gov/show/NCT02452554 |
Active, not recruiting |
Children’s Oncology Group |
2017-06-30 |
| NCT02444884 |
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02444884 |
Completed |
Children’s Oncology Group |
2011-12-31 |
| NCT02441088 |
Theranostics: 68GaDOTATOC and 90YDOTATOC |
https://ClinicalTrials.gov/show/NCT02441088 |
Active, not recruiting |
University of Iowa |
2020-01-31 |
| NCT02441062 |
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02441062 |
Completed |
University of Iowa |
2020-01-20 |
| NCT02395666 |
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission |
https://ClinicalTrials.gov/show/NCT02395666 |
Active, not recruiting |
Spectrum Health Hospitals |
2018-03-01 |
| NCT02390843 |
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors |
https://ClinicalTrials.gov/show/NCT02390843 |
Completed |
Emory University |
2019-09-22 |
| NCT02311621 |
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 |
https://ClinicalTrials.gov/show/NCT02311621 |
Recruiting |
Seattle Children’s Hospital |
2022-11-30 |
| NCT02308527 |
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children |
https://ClinicalTrials.gov/show/NCT02308527 |
Recruiting |
University of Birmingham |
2021-07-31 |
| NCT02307630 |
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study |
https://ClinicalTrials.gov/show/NCT02307630 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-11-30 |
| NCT02304458 |
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas |
https://ClinicalTrials.gov/show/NCT02304458 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-01-31 |
| NCT02298348 |
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02298348 |
Active, not recruiting |
New Approaches to Neuroblastoma Therapy Consortium |
2020-07-31 |
| NCT02245997 |
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02245997 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-09-30 |
| NCT02176967 |
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02176967 |
Recruiting |
Children’s Oncology Group |
2025-09-30 |
| NCT02173093 |
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma |
https://ClinicalTrials.gov/show/NCT02173093 |
Recruiting |
University of Virginia |
2019-12-31 |
| NCT02169609 |
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02169609 |
Active, not recruiting |
Fundació Sant Joan de Déu |
2019-05-31 |
| NCT02163356 |
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02163356 |
Completed |
South Plains Oncology Consortium |
2018-05-31 |
| NCT02162732 |
Molecular-Guided Therapy for Childhood Cancer |
https://ClinicalTrials.gov/show/NCT02162732 |
Active, not recruiting |
Spectrum Health Hospitals |
2020-06-30 |
| NCT02130869 |
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT02130869 |
Completed |
St. Jude Children’s Research Hospital |
2017-12-20 |
| NCT02112617 |
Phase II Study of Proton Radiation Therapy for Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02112617 |
Recruiting |
Massachusetts General Hospital |
2024-03-31 |
| NCT02100930 |
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02100930 |
Completed |
Memorial Sloan Kettering Cancer Center |
2019-03-07 |
| NCT02100891 |
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors |
https://ClinicalTrials.gov/show/NCT02100891 |
Recruiting |
Medical College of Wisconsin |
2020-12-31 |
| NCT02095132 |
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02095132 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-04-30 |
| NCT02076906 |
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors |
https://ClinicalTrials.gov/show/NCT02076906 |
Recruiting |
Children’s National Research Institute |
2020-10-31 |
| NCT01313936 |
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01313936 |
Completed |
University of California, San Francisco |
2014-05-31 |
| NCT01305200 |
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01305200 |
Completed |
Children’s Oncology Group |
2015-06-30 |
| NCT01295762 |
Immunomonitoring of Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01295762 |
Active, not recruiting |
Centre Leon Berard |
2019-03-31 |
| NCT01288573 |
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone |
https://ClinicalTrials.gov/show/NCT01288573 |
Completed |
Sanofi |
2017-05-09 |
| NCT02043899 |
A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02043899 |
Active, not recruiting |
Cancer Research UK |
2020-11-30 |
| NCT02030964 |
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan |
https://ClinicalTrials.gov/show/NCT02030964 |
Active, not recruiting |
New Approaches to Neuroblastoma Therapy Consortium |
2020-06-30 |
| NCT02013336 |
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors |
https://ClinicalTrials.gov/show/NCT02013336 |
Recruiting |
South Plains Oncology Consortium |
2020-12-31 |
| NCT01962103 |
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01962103 |
Completed |
Celgene |
2017-12-05 |
| NCT01953900 |
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01953900 |
Active, not recruiting |
Baylor College of Medicine |
2021-04-30 |
| NCT01875601 |
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT01875601 |
Completed |
National Institutes of Health Clinical Center (CC) |
2015-09-08 |
| NCT01869725 |
Ga-DOTATOC Versus Octreoscan + CT |
https://ClinicalTrials.gov/show/NCT01869725 |
Completed |
University of Iowa |
2018-12-26 |
| NCT01868269 |
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) |
https://ClinicalTrials.gov/show/NCT01868269 |
Recruiting |
Institut Curie |
2027-02-28 |
| NCT01857934 |
Therapy for Children With Advanced Stage Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01857934 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2021-01-31 |
| NCT01850888 |
MIBG for Refractory Neuroblastoma and Pheochromocytoma |
https://ClinicalTrials.gov/show/NCT01850888 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2022-12-31 |
| NCT01822652 |
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN |
https://ClinicalTrials.gov/show/NCT01822652 |
Active, not recruiting |
Baylor College of Medicine |
2015-12-31 |
| NCT01807468 |
Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors |
https://ClinicalTrials.gov/show/NCT01807468 |
Active, not recruiting |
Samsung Medical Center |
2015-12-31 |
| NCT01802567 |
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer |
https://ClinicalTrials.gov/show/NCT01802567 |
Active, not recruiting |
Spectrum Health Hospitals |
2019-12-31 |
| NCT01802138 |
A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01802138 |
Completed |
Seoul National University Hospital |
2016-06-30 |
| NCT01798004 |
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01798004 |
Active, not recruiting |
Children’s Oncology Group |
2015-07-28 |
| NCT01767194 |
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01767194 |
Completed |
National Cancer Institute (NCI) |
2018-06-30 |
| NCT01757626 |
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01757626 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-12-31 |
| NCT01728155 |
European Low and Intermediate Risk Neuroblastoma Protocol |
https://ClinicalTrials.gov/show/NCT01728155 |
Recruiting |
Instituto de Investigacion Sanitaria La Fe |
2021-12-31 |
| NCT01713439 |
Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL |
https://ClinicalTrials.gov/show/NCT01713439 |
Completed |
Baylor College of Medicine |
2001-01-31 |
| NCT01711554 |
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01711554 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-09-14 |
| NCT01704872 |
ch14.18/CHO Bridging Study |
https://ClinicalTrials.gov/show/NCT01704872 |
Completed |
St. Anna Kinderkrebsforschung |
2006-02-28 |
| NCT01704716 |
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) |
https://ClinicalTrials.gov/show/NCT01704716 |
Recruiting |
St. Anna Kinderkrebsforschung |
2019-11-30 |
| NCT01701479 |
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) |
https://ClinicalTrials.gov/show/NCT01701479 |
Active, not recruiting |
St. Anna Kinderkrebsforschung |
2020-12-31 |
| NCT01625351 |
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas |
https://ClinicalTrials.gov/show/NCT01625351 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2020-09-18 |
| NCT01619865 |
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors |
https://ClinicalTrials.gov/show/NCT01619865 |
Active, not recruiting |
University of Iowa |
2017-08-27 |
| NCT01606878 |
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01606878 |
Completed |
Children’s Oncology Group |
2018-12-31 |
| NCT01601535 |
Study of MLN8237 in Combination With Irinotecan and Temozolomide |
https://ClinicalTrials.gov/show/NCT01601535 |
Completed |
New Approaches to Neuroblastoma Therapy Consortium |
2018-07-25 |
| NCT01598454 |
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides |
https://ClinicalTrials.gov/show/NCT01598454 |
Completed |
Laboratorio Elea Phoenix S.A. |
2014-03-31 |
| NCT01592045 |
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01592045 |
Completed |
United Therapeutics |
2014-06-30 |
| NCT01586260 |
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission |
https://ClinicalTrials.gov/show/NCT01586260 |
Active, not recruiting |
Spectrum Health Hospitals |
2021-04-26 |
| NCT01576692 |
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01576692 |
Completed |
St. Jude Children’s Research Hospital |
2014-10-31 |
| NCT01526603 |
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01526603 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2021-02-28 |
| NCT01518413 |
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT01518413 |
Completed |
Children’s National Research Institute |
2015-01-31 |
| NCT01492673 |
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing’s Sarcoma and Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01492673 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-10-31 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01467986 |
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01467986 |
Recruiting |
University of Regensburg |
2020-09-30 |
| NCT01462396 |
Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors |
https://ClinicalTrials.gov/show/NCT01462396 |
Completed |
Children’s Mercy Hospital Kansas City |
2015-12-31 |
| NCT01460901 |
Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01460901 |
Completed |
Children’s Mercy Hospital Kansas City |
2015-01-31 |
| NCT01445379 |
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer |
https://ClinicalTrials.gov/show/NCT01445379 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-04-18 |
| NCT01419834 |
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors |
https://ClinicalTrials.gov/show/NCT01419834 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-08-31 |
| NCT01355679 |
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01355679 |
Completed |
Spectrum Health Hospitals |
2013-09-30 |
| NCT01334515 |
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01334515 |
Completed |
Children’s Oncology Group |
2013-12-31 |
| NCT01331135 |
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors |
https://ClinicalTrials.gov/show/NCT01331135 |
Completed |
Emory University |
2017-08-09 |
| NCT04308330 |
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies |
https://ClinicalTrials.gov/show/NCT04308330 |
Recruiting |
New York Medical College |
2021-12-17 |
| NCT04239092 |
9-ING-41 in Pediatric Patients With Refractory Malignancies. |
https://ClinicalTrials.gov/show/NCT04239092 |
Recruiting |
Actuate Therapeutics Inc. |
2021-04-30 |
| NCT04239040 |
GVAX Plus Checkpoint Blockade in Neuroblastoma |
https://ClinicalTrials.gov/show/NCT04239040 |
Recruiting |
Dana-Farber Cancer Institute |
2027-01-01 |
| NCT04221035 |
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) |
https://ClinicalTrials.gov/show/NCT04221035 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2026-11-30 |
| NCT04049864 |
DNA Vaccination Against Neuroblastoma |
https://ClinicalTrials.gov/show/NCT04049864 |
Recruiting |
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology |
2021-12-31 |
| NCT04040088 |
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04040088 |
Recruiting |
Mayo Clinic |
2023-07-10 |
| NCT04029688 |
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors |
https://ClinicalTrials.gov/show/NCT04029688 |
Recruiting |
Hoffmann-La Roche |
2024-05-16 |
| NCT03979651 |
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma |
https://ClinicalTrials.gov/show/NCT03979651 |
Recruiting |
Hospices Civils de Lyon |
2022-03-31 |
| NCT03860207 |
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers |
https://ClinicalTrials.gov/show/NCT03860207 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2022-02-28 |
| NCT03709680 |
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT03709680 |
Recruiting |
Pfizer |
2021-02-16 |
| NCT03635632 |
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) |
https://ClinicalTrials.gov/show/NCT03635632 |
Recruiting |
Baylor College of Medicine |
2022-06-30 |
| NCT03618381 |
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults |
https://ClinicalTrials.gov/show/NCT03618381 |
Recruiting |
Seattle Children’s Hospital |
2021-06-30 |
| NCT03561259 |
A Study of Therapeutic Iobenguane (131-I) for Relapsed, High-Risk Neuroblastoma Subjects |
https://ClinicalTrials.gov/show/NCT03561259 |
Recruiting |
Jubilant DraxImage Inc. |
2021-03-31 |
| NCT03545542 |
Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03545542 |
Recruiting |
Medical University of Graz |
2022-06-30 |
| NCT03503864 |
Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma |
https://ClinicalTrials.gov/show/NCT03503864 |
Recruiting |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2029-12-30 |
| NCT03496402 |
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) |
https://ClinicalTrials.gov/show/NCT03496402 |
Recruiting |
Institut Curie |
2025-04-01 |
| NCT03478462 |
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma |
https://ClinicalTrials.gov/show/NCT03478462 |
Recruiting |
Cellectar Biosciences, Inc. |
2020-09-30 |
| NCT03434262 |
SJDAWN: St. Jude Children’s Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors |
https://ClinicalTrials.gov/show/NCT03434262 |
Recruiting |
St. Jude Children’s Research Hospital |
2025-02-28 |
| NCT01241162 |
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma |
https://ClinicalTrials.gov/show/NCT01241162 |
Completed |
University of Louisville |
2016-10-31 |
| NCT01222780 |
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer |
https://ClinicalTrials.gov/show/NCT01222780 |
Completed |
Acrotech Biopharma LLC |
2014-12-31 |
| NCT01208454 |
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01208454 |
Completed |
National Cancer Institute (NCI) |
2014-09-30 |
| NCT01192555 |
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01192555 |
Active, not recruiting |
Baylor College of Medicine |
2012-07-31 |
| NCT01183897 |
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow |
https://ClinicalTrials.gov/show/NCT01183897 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-09-25 |
| NCT01183429 |
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01183429 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-09-13 |
| NCT01183416 |
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01183416 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-10-31 |
| NCT01175356 |
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin |
https://ClinicalTrials.gov/show/NCT01175356 |
Completed |
Children’s Oncology Group |
2016-09-28 |
| NCT01169584 |
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients |
https://ClinicalTrials.gov/show/NCT01169584 |
Completed |
SillaJen, Inc. |
2012-03-31 |
| NCT01154816 |
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01154816 |
Completed |
Children’s Oncology Group |
2015-12-31 |
| NCT01132911 |
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas |
https://ClinicalTrials.gov/show/NCT01132911 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-04-13 |
| NCT01125800 |
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB |
https://ClinicalTrials.gov/show/NCT01125800 |
Completed |
Novartis |
2014-10-31 |
| NCT01114555 |
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01114555 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-11-02 |
| NCT01095926 |
Pharmacokinetic Study of Doxorubicin in Children With Cancer |
https://ClinicalTrials.gov/show/NCT01095926 |
Completed |
University Hospital Muenster |
2013-02-28 |
| NCT01059071 |
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide |
https://ClinicalTrials.gov/show/NCT01059071 |
Completed |
Spectrum Health Hospitals |
2014-10-31 |
| NCT01048892 |
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features |
https://ClinicalTrials.gov/show/NCT01048892 |
Completed |
Children’s Oncology Group |
2013-06-30 |
| NCT00960739 |
Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00960739 |
Completed |
Centre Oscar Lambret |
2016-03-31 |
| NCT00939770 |
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00939770 |
Completed |
Children’s Oncology Group |
2018-12-31 |
| NCT00931931 |
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors |
https://ClinicalTrials.gov/show/NCT00931931 |
Completed |
Nationwide Children’s Hospital |
2018-03-19 |
| NCT00923351 |
Therapy to Treat Ewing’s Sarcoma, Rhabdomyosarcoma or Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00923351 |
Completed |
National Institutes of Health Clinical Center (CC) |
2012-08-30 |
| NCT00918320 |
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours |
https://ClinicalTrials.gov/show/NCT00918320 |
Completed |
Gustave Roussy, Cancer Campus, Grand Paris |
2013-10-31 |
| NCT00911560 |
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00911560 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT00885326 |
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00885326 |
Completed |
New Approaches to Neuroblastoma Therapy Consortium |
2014-04-30 |
| NCT00877110 |
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00877110 |
Completed |
Memorial Sloan Kettering Cancer Center |
2019-01-07 |
| NCT00867568 |
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma |
https://ClinicalTrials.gov/show/NCT00867568 |
Completed |
Spectrum Health Hospitals |
2011-09-30 |
| NCT02139397 |
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02139397 |
Active, not recruiting |
Spectrum Health Hospitals |
2020-12-31 |
| NCT00831844 |
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00831844 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01662804 |
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors |
https://ClinicalTrials.gov/show/NCT01662804 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-08 |
| NCT01386619 |
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) |
https://ClinicalTrials.gov/show/NCT01386619 |
Completed |
University Hospital, Basel, Switzerland |
2011-03-31 |
| NCT03332667 |
MIBG With Dinutuximab |
https://ClinicalTrials.gov/show/NCT03332667 |
Recruiting |
New Approaches to Neuroblastoma Therapy Consortium |
2021-09-30 |
| NCT02107963 |
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors |
https://ClinicalTrials.gov/show/NCT02107963 |
Completed |
National Institutes of Health Clinical Center (CC) |
2016-08-15 |
| NCT01041638 |
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01041638 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-04-14 |
| NCT00793845 |
Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00793845 |
Completed |
Samsung Medical Center |
2015-01-31 |
| NCT00793351 |
Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation |
https://ClinicalTrials.gov/show/NCT00793351 |
Completed |
Samsung Medical Center |
2013-11-30 |
| NCT00790413 |
Haploidentical Stem Cell Transplantation in Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00790413 |
Active, not recruiting |
Lund University Hospital |
2020-12-31 |
| NCT00788125 |
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors |
https://ClinicalTrials.gov/show/NCT00788125 |
Active, not recruiting |
City of Hope Medical Center |
2023-09-30 |
| NCT00782145 |
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families |
https://ClinicalTrials.gov/show/NCT00782145 |
Completed |
Tufts Medical Center |
2011-06-30 |
| NCT00754286 |
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer |
https://ClinicalTrials.gov/show/NCT00754286 |
Completed |
Albert Einstein College of Medicine |
2011-07-31 |
| NCT00743496 |
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma |
https://ClinicalTrials.gov/show/NCT00743496 |
Completed |
St. Jude Children’s Research Hospital |
2014-04-01 |
| NCT00726934 |
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients |
https://ClinicalTrials.gov/show/NCT00726934 |
Completed |
Indiana University |
2017-01-31 |
| NCT00716976 |
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy |
https://ClinicalTrials.gov/show/NCT00716976 |
Completed |
Children’s Oncology Group |
2015-04-30 |
| NCT00703222 |
A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells |
https://ClinicalTrials.gov/show/NCT00703222 |
Active, not recruiting |
Baylor College of Medicine |
2011-05-31 |
| NCT00659984 |
N2007-01: Ultratraceâ„¢ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00659984 |
Completed |
Molecular Insight Pharmaceuticals, Inc. |
2010-08-31 |
| NCT00646230 |
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00646230 |
Completed |
Children’s Hospital Los Angeles |
2012-03-31 |
| NCT00644696 |
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00644696 |
Completed |
University of Michigan Rogel Cancer Center |
2012-07-31 |
| NCT00601003 |
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma |
https://ClinicalTrials.gov/show/NCT00601003 |
Active, not recruiting |
Spectrum Health Hospitals |
2020-05-01 |
| NCT00638898 |
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
https://ClinicalTrials.gov/show/NCT00638898 |
Active, not recruiting |
City of Hope Medical Center |
2020-09-01 |
| NCT00578864 |
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00578864 |
Completed |
Baylor College of Medicine |
2009-07-31 |
| NCT00567567 |
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00567567 |
Active, not recruiting |
Children’s Oncology Group |
2015-02-27 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00520936 |
A Study of Pemetrexed in Children With Recurrent Cancer |
https://ClinicalTrials.gov/show/NCT00520936 |
Completed |
Eli Lilly and Company |
2010-02-28 |
| NCT00509353 |
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00509353 |
Completed |
Children’s Hospital Los Angeles |
2010-10-31 |
| NCT00503724 |
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors |
https://ClinicalTrials.gov/show/NCT00503724 |
Completed |
Pediatric Brain Tumor Consortium |
2010-05-31 |
| NCT00499616 |
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00499616 |
Active, not recruiting |
Children’s Oncology Group |
2014-06-30 |
| NCT00492167 |
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00492167 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-08-31 |
| NCT00486564 |
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00486564 |
Completed |
University of Vermont |
2007-11-30 |
| NCT00471679 |
Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00471679 |
Completed |
Memorial Sloan Kettering Cancer Center |
2010-02-28 |
| NCT00450827 |
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00450827 |
Completed |
Memorial Sloan Kettering Cancer Center |
2015-08-31 |
| NCT00450307 |
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00450307 |
Completed |
Memorial Sloan Kettering Cancer Center |
2013-04-30 |
| NCT00445965 |
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer |
https://ClinicalTrials.gov/show/NCT00445965 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT00436852 |
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment |
https://ClinicalTrials.gov/show/NCT00436852 |
Completed |
Children’s Oncology Group |
2010-09-01 |
| NCT00436657 |
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00436657 |
Completed |
M.D. Anderson Cancer Center |
2011-04-30 |
| NCT00410657 |
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00410657 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-11-30 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00407433 |
Clinical Studies of Gemcitabine-Oxaliplatin |
https://ClinicalTrials.gov/show/NCT00407433 |
Completed |
Gustave Roussy, Cancer Campus, Grand Paris |
NA |
| NCT00405327 |
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00405327 |
Completed |
University of Michigan Rogel Cancer Center |
2009-06-30 |
| NCT01019850 |
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT01019850 |
Completed |
New Approaches to Neuroblastoma Therapy Consortium |
2014-12-31 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00365755 |
Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00365755 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00357500 |
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer |
https://ClinicalTrials.gov/show/NCT00357500 |
Completed |
Dana-Farber Cancer Institute |
2013-02-28 |
| NCT00336531 |
Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00336531 |
Completed |
Samsung Medical Center |
2008-06-30 |
| NCT00331643 |
Ixabepilone in Treating Young Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00331643 |
Completed |
National Cancer Institute (NCI) |
2007-10-31 |
| NCT00311584 |
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00311584 |
Completed |
Children’s Oncology Group |
2009-03-31 |
| NCT00309907 |
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00309907 |
Completed |
Children’s Oncology Group |
2011-09-30 |
| NCT00303940 |
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors |
https://ClinicalTrials.gov/show/NCT00303940 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00295919 |
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00295919 |
Completed |
Children’s Hospital Los Angeles |
2014-03-31 |
| NCT00293384 |
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00293384 |
Completed |
Barbara Ann Karmanos Cancer Institute |
2009-06-30 |
| NCT00293319 |
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00293319 |
Completed |
University of California, San Francisco |
2006-03-31 |
| NCT00276679 |
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00276679 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00253435 |
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00253435 |
Completed |
Children’s Hospital Los Angeles |
2012-12-31 |
| NCT00217412 |
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia |
https://ClinicalTrials.gov/show/NCT00217412 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00206388 |
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement |
https://ClinicalTrials.gov/show/NCT00206388 |
Completed |
Baylor College of Medicine |
2008-04-30 |
| NCT00187109 |
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy |
https://ClinicalTrials.gov/show/NCT00187109 |
Completed |
St. Jude Children’s Research Hospital |
2007-02-28 |
| NCT00186862 |
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00186862 |
Completed |
St. Jude Children’s Research Hospital |
2000-04-30 |
| NCT00186849 |
Therapy for Children With Advanced Stage High Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00186849 |
Completed |
St. Jude Children’s Research Hospital |
2001-04-30 |
| NCT00165139 |
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas |
https://ClinicalTrials.gov/show/NCT00165139 |
Completed |
Dana-Farber Cancer Institute |
2000-11-30 |
| NCT00152126 |
Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas |
https://ClinicalTrials.gov/show/NCT00152126 |
Completed |
St. Jude Children’s Research Hospital |
2005-08-31 |
| NCT00135135 |
Therapy for Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00135135 |
Completed |
St. Jude Children’s Research Hospital |
2007-06-30 |
| NCT00132158 |
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00132158 |
Completed |
St. Jude Children’s Research Hospital |
2011-10-31 |
| NCT00126412 |
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00126412 |
Completed |
GE Healthcare |
2006-09-27 |
| NCT00118326 |
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease |
https://ClinicalTrials.gov/show/NCT00118326 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00112645 |
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00112645 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00109993 |
Campath-1H + FK506 and Methylprednisolone for GVHD |
https://ClinicalTrials.gov/show/NCT00109993 |
Completed |
Case Comprehensive Cancer Center |
2006-06-30 |
| NCT00089245 |
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer |
https://ClinicalTrials.gov/show/NCT00089245 |
Active, not recruiting |
Y-mAbs Therapeutics |
2019-07-01 |
| NCT00101270 |
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00101270 |
Completed |
National Cancer Institute (NCI) |
2007-09-30 |
| NCT00098865 |
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00098865 |
Completed |
Dana-Farber Cancer Institute |
2010-06-30 |
| NCT00093821 |
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00093821 |
Completed |
National Cancer Institute (NCI) |
2007-08-31 |
| NCT00093353 |
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00093353 |
Completed |
Children’s Hospital Los Angeles |
2006-07-31 |
| NCT00002543 |
Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin’s Lymphoma, or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00002543 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00091182 |
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment |
https://ClinicalTrials.gov/show/NCT00091182 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00002730 |
Chemotherapy in Treating Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00002730 |
Completed |
Children’s Hospital Los Angeles |
NA |
| NCT00002458 |
Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission |
https://ClinicalTrials.gov/show/NCT00002458 |
Completed |
Memorial Sloan Kettering Cancer Center |
2001-09-30 |
| NCT00002634 |
Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00002634 |
Completed |
Memorial Sloan Kettering Cancer Center |
2004-09-30 |
| NCT00089258 |
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment |
https://ClinicalTrials.gov/show/NCT00089258 |
Completed |
Memorial Sloan Kettering Cancer Center |
2006-11-30 |
| NCT00003661 |
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00003661 |
Completed |
Roswell Park Cancer Institute |
1999-11-30 |
| NCT00085930 |
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients |
https://ClinicalTrials.gov/show/NCT00085930 |
Active, not recruiting |
Baylor College of Medicine |
2010-01-31 |
| NCT00002740 |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00002740 |
Completed |
Children’s Oncology Group |
2004-03-31 |
| NCT00003846 |
Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors |
https://ClinicalTrials.gov/show/NCT00003846 |
Completed |
Children’s Oncology Group |
2004-10-31 |
| NCT00082758 |
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00082758 |
Completed |
Children’s Oncology Group |
2008-02-29 |
| NCT00082654 |
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients |
https://ClinicalTrials.gov/show/NCT00082654 |
Completed |
Fred Hutchinson Cancer Research Center |
2004-10-31 |
| NCT00083135 |
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00083135 |
Completed |
Children’s Hospital Los Angeles |
2006-02-28 |
| NCT00002803 |
Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00002803 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00002802 |
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00002802 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00003887 |
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00003887 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00010283 |
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon |
https://ClinicalTrials.gov/show/NCT00010283 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00080873 |
Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00080873 |
Completed |
Children’s Oncology Group |
2006-11-30 |
| NCT00003107 |
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00003107 |
Completed |
Indiana University |
NA |
| NCT00007813 |
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors |
https://ClinicalTrials.gov/show/NCT00007813 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2005-02-01 |
| NCT00002825 |
Docetaxel in Treating Children With Recurrent Solid Tumors |
https://ClinicalTrials.gov/show/NCT00002825 |
Completed |
National Cancer Institute (NCI) |
2004-12-31 |
| NCT00003425 |
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect |
https://ClinicalTrials.gov/show/NCT00003425 |
Completed |
University of Kentucky |
2002-07-31 |
| NCT00077454 |
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00077454 |
Completed |
National Cancer Institute (NCI) |
2007-09-30 |
| NCT00004157 |
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin’s Lymphoma, Hodgkin’s Disease, Breast Cancer, or Other Solid Tumors |
https://ClinicalTrials.gov/show/NCT00004157 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00002748 |
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00002748 |
Completed |
St. Jude Children’s Research Hospital |
2007-08-31 |
| NCT00075634 |
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00075634 |
Completed |
National Cancer Institute (NCI) |
2007-09-30 |
| NCT00006480 |
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00006480 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00005978 |
N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00005978 |
Completed |
New Approaches to Neuroblastoma Therapy Consortium |
2004-12-31 |
| NCT00003191 |
Fenretinide in Treating Children With Solid Tumors |
https://ClinicalTrials.gov/show/NCT00003191 |
Completed |
National Cancer Institute (NCI) |
2005-03-31 |
| NCT00072358 |
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00072358 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-12-31 |
| NCT00003141 |
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors |
https://ClinicalTrials.gov/show/NCT00003141 |
Completed |
Children’s Oncology Group |
2007-12-31 |
| NCT00005576 |
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00005576 |
Completed |
National Cancer Institute (NCI) |
2002-03-31 |
| NCT00003234 |
Vinorelbine in Treating Children With Recurrent or Refractory Cancers |
https://ClinicalTrials.gov/show/NCT00003234 |
Completed |
Children’s Oncology Group |
2006-03-31 |
| NCT00017368 |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00017368 |
Completed |
Children’s Oncology Group |
2005-09-30 |
| NCT00070200 |
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00070200 |
Completed |
Children’s Oncology Group |
2006-09-30 |
| NCT00066599 |
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy |
https://ClinicalTrials.gov/show/NCT00066599 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00064311 |
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00064311 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00062855 |
Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00062855 |
Completed |
Baylor College of Medicine |
2001-08-31 |
| NCT00003408 |
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer |
https://ClinicalTrials.gov/show/NCT00003408 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00003203 |
Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors |
https://ClinicalTrials.gov/show/NCT00003203 |
Completed |
Children’s Oncology Group |
2007-10-31 |
| NCT00060372 |
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
https://ClinicalTrials.gov/show/NCT00060372 |
Completed |
National Cancer Institute (NCI) |
2008-04-30 |
| NCT00030667 |
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood |
https://ClinicalTrials.gov/show/NCT00030667 |
Completed |
National Cancer Institute (NCI) |
2005-12-31 |
| NCT00003484 |
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors |
https://ClinicalTrials.gov/show/NCT00003484 |
Completed |
Duke University |
2003-11-30 |
| NCT00053326 |
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00053326 |
Completed |
National Cancer Institute (NCI) |
2006-03-31 |
| NCT00053118 |
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer |
https://ClinicalTrials.gov/show/NCT00053118 |
Completed |
Roswell Park Cancer Institute |
2004-07-31 |
| NCT00004078 |
Irinotecan in Treating Children With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00004078 |
Completed |
Children’s Oncology Group |
2007-10-31 |
| NCT00049023 |
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00049023 |
Completed |
University of Iowa |
2011-08-31 |
| NCT00040911 |
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00040911 |
Completed |
Children’s Oncology Group |
2009-10-31 |
| NCT00040872 |
Multiple Therapies in Treating Patients With Advanced Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00040872 |
Completed |
Memorial Sloan Kettering Cancer Center |
2007-01-31 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00037011 |
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00037011 |
Completed |
Memorial Sloan Kettering Cancer Center |
2005-01-31 |
| NCT00036959 |
ABT-751 in Treating Young Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00036959 |
Completed |
National Institutes of Health Clinical Center (CC) |
2010-02-28 |
| NCT00030108 |
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven’t Responded to Therapy |
https://ClinicalTrials.gov/show/NCT00030108 |
Completed |
National Institutes of Health Clinical Center (CC) |
2010-03-31 |
| NCT00026312 |
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00026312 |
Active, not recruiting |
National Cancer Institute (NCI) |
2012-01-12 |
| NCT00025649 |
Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00025649 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00025623 |
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00025623 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00025610 |
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00025610 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00025597 |
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. |
https://ClinicalTrials.gov/show/NCT00025597 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00025428 |
Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00025428 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00024258 |
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors |
https://ClinicalTrials.gov/show/NCT00024258 |
Completed |
Memorial Sloan Kettering Cancer Center |
2009-05-31 |
| NCT00020527 |
Caspofungin Acetate in Treating Children With Fever and Neutropenia |
https://ClinicalTrials.gov/show/NCT00020527 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00020150 |
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors |
https://ClinicalTrials.gov/show/NCT00020150 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00017225 |
Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00017225 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00012181 |
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00012181 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00006102 |
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00006102 |
Completed |
National Cancer Institute (NCI) |
2006-06-30 |
| NCT00005955 |
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors |
https://ClinicalTrials.gov/show/NCT00005955 |
Completed |
Duke University |
NA |
| NCT00005952 |
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors |
https://ClinicalTrials.gov/show/NCT00005952 |
Completed |
Duke University |
2005-11-30 |
| NCT00005835 |
N99-02: Melphalan and Buthionine Sulfoximine |
https://ClinicalTrials.gov/show/NCT00005835 |
Completed |
New Approaches to Neuroblastoma Therapy Consortium |
2014-12-31 |
| NCT00004188 |
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00004188 |
Completed |
Children’s Oncology Group |
2007-10-31 |
| NCT00004110 |
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00004110 |
Completed |
Memorial Sloan Kettering Cancer Center |
2004-09-30 |
| NCT00003750 |
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors |
https://ClinicalTrials.gov/show/NCT00003750 |
Completed |
Children’s Oncology Group |
2005-01-31 |
| NCT00003737 |
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00003737 |
Completed |
Memorial Sloan Kettering Cancer Center |
2006-09-30 |
| NCT00003461 |
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors |
https://ClinicalTrials.gov/show/NCT00003461 |
Completed |
Duke University |
2005-02-28 |
| NCT00003119 |
Surgery in Treating Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00003119 |
Completed |
Children’s Oncology Group |
2006-03-31 |
| NCT00003093 |
Combination Chemotherapy in Treating Children With Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00003093 |
Completed |
Children’s Oncology Group |
2006-09-30 |
| NCT00003023 |
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer |
https://ClinicalTrials.gov/show/NCT00003023 |
Completed |
Memorial Sloan Kettering Cancer Center |
2005-01-31 |
| NCT00003022 |
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer |
https://ClinicalTrials.gov/show/NCT00003022 |
Completed |
Memorial Sloan Kettering Cancer Center |
2005-01-31 |
| NCT00002560 |
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00002560 |
Completed |
Memorial Sloan Kettering Cancer Center |
2005-04-30 |
| NCT00002515 |
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer |
https://ClinicalTrials.gov/show/NCT00002515 |
Completed |
Memorial Sloan Kettering Cancer Center |
2005-04-30 |
| NCT00001565 |
Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy |
https://ClinicalTrials.gov/show/NCT00001565 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001509 |
A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms’ Tumor |
https://ClinicalTrials.gov/show/NCT00001509 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00048386 |
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy |
https://ClinicalTrials.gov/show/NCT00048386 |
Completed |
Baylor College of Medicine |
2004-12-31 |
| NCT00084422 |
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00084422 |
Completed |
New Approaches to Neuroblastoma Therapy Consortium |
2009-09-30 |
| NCT00028522 |
R(+)XK469 in Treating Patients With Advanced Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00028522 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00001335 |
New Therapeutic Strategies for Patients With Ewing’s Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma |
https://ClinicalTrials.gov/show/NCT00001335 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |